Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy

Circulation

Volumn 110, Issue 8, 2004, Pages 955-961

  Nikolaidis, Lazaros A ^a,b   Elahi, Dariush ^a,b,c   Hentosz, Teresa ^a,b   Doverspike, Aaron ^a,b   Huerbin, Rhonda ^a,b   Zourelias, Lee ^a,b   Stolarski, Carol ^a,b   Shen, You Tang ^a,b   Shannon, Richard P ^a,b  

^a ALLEGHENY GENERAL HOSPITAL   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Cardiomyopathy; Glucose; Insulin; Ventricles

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; RECOMBINANT GLUCAGON LIKE PEPTIDE 1; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTINUOUS INFUSION; CONTROLLED STUDY; DOG; DRUG EFFECT; DRUG MECHANISM; GLUCOSE TRANSPORT; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE FUNCTION; HEART OUTPUT; HEART PACING; HEART RATE; HEART STROKE VOLUME; HEMODYNAMICS; INSULIN SENSITIVITY; MINIPUMP; NONHUMAN; PRIORITY JOURNAL; SYSTEMIC VASCULAR RESISTANCE;

ANIMALS; BLOOD GLUCOSE; CARDIAC PACING, ARTIFICIAL; CARDIOMYOPATHY, DILATED; CONSCIOUSNESS; DISEASE MODELS, ANIMAL; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ENERGY METABOLISM; FATTY ACIDS; FEMALE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; GLUCOSE CLAMP TECHNIQUE; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HYPERINSULINISM; INFUSIONS, INTRAVENOUS; INSULIN RESISTANCE; MALE; MYOCARDIUM; OXYGEN CONSUMPTION; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS; RECOMBINANT PROTEINS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 4344605042     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000139339.85840.DD     Document Type: Article

References (26)

1. Diaz R, Paolasso EA, Piegas LS, et al. Metabolic modulation of acute myocardial infarction: the ECLA (Estudios Cardiologicos Latinoamerica) Collaborative Group. Circulation. 1998;98:2227-2234.
2. Marano L, Bestetti A, Lomuscio A, et al. Effects of infusion of glucose-insulin-potassium on myocardial function after a recent myocardial infarction. Acta Cardiol. 2000;55:9-15.
3. Depre C, Vanoverschelde JL, Taegtmeyer H. Glucose for the heart. Circulation. 1999;99:578-588.
4. Depre C, Rider MH, Hue L. Mechanisms of control of heart glycolysis. Eur J Biochem. 1998;258:277-290.
5. 18F]FDG in patients with congestive heart failure. J Nucl Med. 2001;42:55-62.
6. Wallhaus TR, Taylor M, DeGrado TR, et al. Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure. Circulation. 2001;103:2441-2446.
7. Davila-Roman VG, Vedala G, Herrero P, et al. Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 2002;40:271-277.
8. Osorio JC, Stanley WC, Linke A, et al. Impaired myocardial fatty acid oxidation and reduced protein expression of retinoid X receptor-α in pacing-induced heart failure. Circulation. 2002;106:606-612.
9. Razeghi P, Young ME, Alcorn JL, et al. Metabolic gene expression in fetal and failing human heart. Circulation. 2001;104:2923-2931.
10. Paolisso G, De Riu S, Marrazzo G, et al. Insulin resistance and hyperinsulinemia in patients with chronic congestive heart failure. Metab Clin Exp. 1991;40:972-977.
11. Paolisso G, Tagliamonte MR, Rizzo MR, et al. Prognostic importance of insulin-mediated glucose uptake in aged patients with congestive heart failure secondary to mitral and/or aortic valve disease. Am J Cardiol. 1999;83:1338-1344.
12. Coats AJ, Anker S. Insulin resistance in chronic heart failure. J Cardiovasc Phamacol. 2000;35(suppl 4):S9-S14.
13. Swan JW, Anker SD, Walton C, et al. Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. J Am Coll Cardiol. 1997;30:527-532.
14. Paolisso G, Gambardella A, Galzerano D, et al. Total-body myocardial substrate oxidation in congestive heart failure. Metabolism. 1994;43: 174-179.
15. Nikolaidis LA, Sturzu A, Stolarski C. et al. The development of myocardial insulin resistance in conscious dogs with advanced dilated cardiomyopathy. Cardiol Res. 2004;61:297-306.
16. Shen W, Asai L, Uechi M, et al. Progressive loss of myocardial ATP due to a loss of total purines during the development of heart failure in dogs: a compensatory role for the parallel loss of creatine. Circulation. 1999; 100:2113-2118.
17. Perfetti R, Merkel P. Glucagon-like peptide-1: a major regulator of pancreatic beta-cell function. Eur J Endocrinol. 2000;143:717-725.
18. Doyle ME, Egan JM. Glucagon-like peptide-1. Recent Prog Harm Res. 2001;56:377-399.
19. Egan JM, Meneilly GS, Habener JF, et al. Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state. J Clin Endocrinol Metab. 2002;87:3768-3773.
20. Meneilly GS, McIntosh CH, Pederson RA, et al. Effect of glucagon-like peptide 1 on non-insulin-mediated glucose uptake in the elderly patient with diabetes. Diabetes Care. 2001;24:1951-1956.
21. Egan JM, Clocquet AR, Elahi D. The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. J Clin Endocrinol Metab. 2002;87:1282-1290.
22. Vila Petroff MG, Egan JM, Wang X, et al. Glucagon-like peptide-1 increases cAMP but fails to augment contraction in adult rat cardiac myocytes. Circ Res. 2001;89:445-452.
23. Barragan JM, Rodriguez R, Blazquez E. Changes in arterial blood pressure and heart rate induced by glucagons like peptide-1 (7-36) amide in rats. Am J Physiol. 1994;29:E459-E466.
24. Barragan JM, Eng J, Rodriguez R, et al. Neural contribution to the effect of glucagons-like peptide (7-36) amide on arterial blood pressure in rats. Am J Physiol. 1999;277:E784-E791.
25. Yamamoto H, Lee CE, Marcus JN, et al. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest. 2002;110:43-52.
26. Hui H, Farilla L, Merkel P, et al. The short half-life of glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects. Eur J Endocrinol. 2002;146:863-869.